Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Small cell lung cancer.

Taimur Sher1, Grace K Dy, Alex A Adjei

  • 1Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA.

Mayo Clinic Proceedings
|March 5, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Defining Cardiovascular Endpoints in Oncology Trials: Challenges and Opportunities: A Scientific Statement From the American Heart Association.

Circulation·2026
Same author

Defining Cardiovascular Endpoints in Oncology Trials: Challenges and Opportunities: A Scientific Statement From the American Heart Association.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

When Shorter Is Sweeter: Early Discontinuation of Immune Checkpoint Inhibitors in Advanced NSCLC.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same author

Fianlimab, a human lymphocyte activation gene-3 monoclonal antibody, in combination with cemiplimab: Tumor-specific expansion cohorts in advanced malignancies.

Cancer·2026
Same author

The Impact of Immunotherapy on Incidence of Second Primary Malignancies: A Surrogate for Antitumor Surveillance Activation.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

A Phase I Study of Nimotuzumab With Nivolumab in Advanced Non-small Cell Lung Cancer and Head and Neck Squamous Cell Cancer.

Cureus·2026
Same journal

37-Year-Old Woman With Jaundice.

Mayo Clinic proceedings·2026
Same journal

34-Year-Old Woman With An Unidentified Overdose.

Mayo Clinic proceedings·2026
Same journal

Use of Bronchoscopic Cryobiopsy in Evaluating Interstitial Lung Disease: Radiologic Predictors of Diagnostic Yield and Safety.

Mayo Clinic proceedings·2026
Same journal

Advancing Pulmonary Fibrosis Care: Integrating Genomic Insights Into Clinical Practice.

Mayo Clinic proceedings·2026
Same journal

RAAS Inhibition in the ICU: Stop, Continue, or Restart?

Mayo Clinic proceedings·2026
Same journal

Chronic Kidney Disease-In the Limelight, July 2026.

Mayo Clinic proceedings·2026
See all related articles

Small cell lung cancer, a common lung carcinoma, often presents with paraneoplastic syndromes. While chemotherapy and radiation offer sensitivity, cures remain challenging, with platinum/etoposide and thoracic radiotherapy showing survival benefits.

Area of Science:

  • Oncology
  • Pulmonology
  • Radiation Oncology

Background:

  • Small cell lung cancer (SCLC) constitutes about 15% of lung cancers.
  • SCLC is frequently linked to paraneoplastic syndromes like SIADH and Lambert-Eaton myasthenic syndrome.
  • Early metastasis limits surgical intervention in SCLC.

Purpose of the Study:

  • To review the current therapeutic strategies for small cell lung cancer.
  • To evaluate the efficacy of chemotherapy, radiation, and novel agents in SCLC treatment.
  • To summarize the role of thoracic radiotherapy and prophylactic cranial irradiation.

Main Methods:

  • Review of existing literature on small cell lung cancer treatment.
  • Analysis of standard chemotherapeutic regimens, including platinum and etoposide.

Related Experiment Videos

  • Evaluation of the impact of thoracic radiotherapy (TRT) timing and concurrency with chemotherapy.

    • Main Results:

    • Platinum and etoposide is the standard chemotherapy for SCLC.
    • Concurrent thoracic radiotherapy (TRT) with chemotherapy improves survival by approximately 5% compared to chemotherapy alone.
    • Prophylactic cranial radiation reduces central nervous system recurrence and improves survival.
    • Dose intensification, density, or maintenance chemotherapy did not yield significant survival benefits.
    • Novel agents like bevacizumab show early promise but require further evaluation.

    Conclusions:

    • SCLC treatment relies heavily on chemotherapy and radiation due to its metastatic nature.
    • Concurrent and early administration of TRT enhances survival outcomes in limited-stage SCLC.
    • Prophylactic cranial irradiation is crucial for preventing CNS recurrence and improving overall survival.